000138111 001__ 138111
000138111 005__ 20240808134014.0
000138111 0247_ $$2doi$$a10.1016/j.biomaterials.2015.07.029
000138111 0247_ $$2pmid$$apmid:26222283
000138111 0247_ $$2ISSN$$a0142-9612
000138111 0247_ $$2ISSN$$a1878-5905
000138111 0247_ $$2altmetric$$aaltmetric:108386780
000138111 037__ $$aDZNE-2020-04433
000138111 041__ $$aEnglish
000138111 082__ $$a570
000138111 1001_ $$0P:(DE-2719)2810324$$aSchurig, Katja$$b0$$eFirst author$$udzne
000138111 245__ $$aNeurotropic growth factors and glycosaminoglycan based matrices to induce dopaminergic tissue formation.
000138111 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2015
000138111 264_1 $$2Crossref$$3print$$bElsevier BV$$c2015-10-01
000138111 3367_ $$2DRIVER$$aarticle
000138111 3367_ $$2DataCite$$aOutput Types/Journal article
000138111 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1723117195_2209
000138111 3367_ $$2BibTeX$$aARTICLE
000138111 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000138111 3367_ $$00$$2EndNote$$aJournal Article
000138111 520__ $$aCurrent cell replacement therapies in Parkinson's disease (PD) are limited by low survival of transplanted cell and lacking regeneration of neuronal circuitries. Therefore, bioartificial cell carriers and growth/differentiation factors are applied to improve the integration of transplants and maximize newly generated and/or residual dopaminergic function. In this work, biohybrid poly(ethylene glycol) (starPEG)-heparin hydrogels releasing fibroblast growth factor 2 (FGF-2) and glial-derived neurotrophic factor (GDNF) were used to trigger dopaminergic tissue formation by primary murine midbrain cells in vitro. Matrix-delivered FGF-2 enhanced cell viability while release of GDNF had a pro-neuronal/dopaminergic effect. Combined delivery of both factors from the glycosaminoglycan-based matrices resulted in a tremendous improvement in survival and maturation capacity of dopaminergic neurons as obvious from tyrosine hydroxylase expression and neurite outgrowth. The reported data demonstrate that glycosaminoglycan-based hydrogels can facilitate the administration of neurotrophic factors and are therefore instrumental in potential future treatments of PD.
000138111 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000138111 542__ $$2Crossref$$i2015-10-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000138111 588__ $$aDataset connected to CrossRef, PubMed,
000138111 650_7 $$2NLM Chemicals$$aGlial Cell Line-Derived Neurotrophic Factor
000138111 650_7 $$2NLM Chemicals$$aGlycosaminoglycans
000138111 650_7 $$2NLM Chemicals$$aHydrogels
000138111 650_7 $$2NLM Chemicals$$aNerve Growth Factors
000138111 650_7 $$0103107-01-3$$2NLM Chemicals$$aFibroblast Growth Factor 2
000138111 650_7 $$03WJQ0SDW1A$$2NLM Chemicals$$aPolyethylene Glycols
000138111 650_7 $$09005-49-6$$2NLM Chemicals$$aHeparin
000138111 650_2 $$2MeSH$$aAnimals
000138111 650_2 $$2MeSH$$aCell Differentiation: drug effects
000138111 650_2 $$2MeSH$$aCell Survival: drug effects
000138111 650_2 $$2MeSH$$aCells, Cultured
000138111 650_2 $$2MeSH$$aDopaminergic Neurons: cytology
000138111 650_2 $$2MeSH$$aDopaminergic Neurons: drug effects
000138111 650_2 $$2MeSH$$aDrug Liberation
000138111 650_2 $$2MeSH$$aFemale
000138111 650_2 $$2MeSH$$aFetus: cytology
000138111 650_2 $$2MeSH$$aFibroblast Growth Factor 2: pharmacology
000138111 650_2 $$2MeSH$$aGlial Cell Line-Derived Neurotrophic Factor: pharmacology
000138111 650_2 $$2MeSH$$aGlycosaminoglycans: pharmacology
000138111 650_2 $$2MeSH$$aHeparin: chemistry
000138111 650_2 $$2MeSH$$aHydrogels: chemical synthesis
000138111 650_2 $$2MeSH$$aMesencephalon: cytology
000138111 650_2 $$2MeSH$$aMice, Inbred C57BL
000138111 650_2 $$2MeSH$$aNerve Growth Factors: pharmacology
000138111 650_2 $$2MeSH$$aNeural Stem Cells: cytology
000138111 650_2 $$2MeSH$$aNeural Stem Cells: drug effects
000138111 650_2 $$2MeSH$$aNeurites: drug effects
000138111 650_2 $$2MeSH$$aNeurites: metabolism
000138111 650_2 $$2MeSH$$aNeuroglia: cytology
000138111 650_2 $$2MeSH$$aNeuroglia: drug effects
000138111 650_2 $$2MeSH$$aPolyethylene Glycols: chemical synthesis
000138111 650_2 $$2MeSH$$aTissue Engineering: methods
000138111 7001_ $$aZieris, Andrea$$b1
000138111 7001_ $$0P:(DE-2719)2811732$$aHermann, Andreas$$b2$$udzne
000138111 7001_ $$aFreudenberg, Uwe$$b3
000138111 7001_ $$aHeidel, Sabine$$b4
000138111 7001_ $$aGrimmer, Milauscha$$b5
000138111 7001_ $$0P:(DE-2719)9000306$$aStorch, Alexander$$b6$$udzne
000138111 7001_ $$0P:(DE-HGF)0$$aWerner, Carsten$$b7$$eCorresponding author
000138111 77318 $$2Crossref$$3journal-article$$a10.1016/j.biomaterials.2015.07.029$$b : Elsevier BV, 2015-10-01$$p205-213$$tBiomaterials$$v67$$x0142-9612$$y2015
000138111 773__ $$0PERI:(DE-600)2004010-6$$a10.1016/j.biomaterials.2015.07.029$$gVol. 67, p. 205 - 213$$p205-213$$q67<205 - 213$$tBiomaterials$$v67$$x0142-9612$$y2015
000138111 8564_ $$uhttps://pub.dzne.de/record/138111/files/DZNE-2020-04433_Restriced.pdf
000138111 8564_ $$uhttps://pub.dzne.de/record/138111/files/DZNE-2020-04433_Restriced.pdf?subformat=pdfa$$xpdfa
000138111 909CO $$ooai:pub.dzne.de:138111$$pVDB
000138111 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000138111 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000138111 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000306$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000138111 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000138111 9141_ $$y2015
000138111 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000138111 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMATERIALS : 2017
000138111 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000138111 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000138111 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000138111 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000138111 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000138111 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000138111 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000138111 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000138111 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000138111 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000138111 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000138111 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBIOMATERIALS : 2017
000138111 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x0
000138111 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x1
000138111 980__ $$ajournal
000138111 980__ $$aVDB
000138111 980__ $$aI:(DE-2719)5000014
000138111 980__ $$aI:(DE-2719)1510100
000138111 980__ $$aUNRESTRICTED